Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business funding round

Heidi raises $340M at $900M valuation

Analysis based on 7 articles · First reported Sep 22, 2026 · Last updated Sep 23, 2026

Sentiment
25
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The round signals continued strong venture appetite for healthcare AI, lifting sentiment for clinical documentation and agentic healthcare software peers and their investors. It pressures competitors such as Ambience Healthcare, Abridge, and Microsoft-owned Nuance, while validating the enterprise SaaS growth trajectory that underpins Heidi's $900 million valuation.

healthcare technology artificial intelligence venture capital

Heidi, an Australian healthcare technology company founded in Melbourne in 2021 by Dr. Thomas Kelly, Waleed Mussa, and Liu Yu, announced on September 22, 2026 a $340 million funding package valuing the company at $900 million. The package comprises a $100 million Series C equity round led by Blackbird II ApS with participation from existing investors Phoenix Court, Point72 Asset Management, and Headline, plus a separate $240 million growth investment led by General Catalyst's Customer Value Fund. The capital will fund global expansion and development of supervised AI agents that handle administrative and clinical workflows under physician oversight, moving Heidi beyond its original AI clinical documentation scribe. Heidi's platform reportedly supports approximately 2.8 million patient visits per week across 190 countries and 110 languages, and has supported more than 175 million patient visits and over 67 million clinical hours since launch. Annual recurring revenue reportedly grew from $1 million to $50 million in about two years, reaching that level in April 2026. Deployments include Beth Israel Lahey Health in the United States, Bret Engemann Midlands in the United Kingdom as sole supplier, The Royal Children s Hospital, Australia — Queensland Children s Hospital, and Australia — Metro South Health in Australia, and every emergency department in New Zealand. Heidi also named Toronto as its North American headquarters and partnered with R1 RCM to integrate its documentation technology into R1's revenue operating system. Dr. Simon Kos, formerly Chief Medical Officer at Microsoft, joined as Heidi's CMO during the Series B round. The company said forthcoming agentic capabilities will not be available in the United Kingdom or European Union.

100 Heidi raised funding
85 Blackbird II ApS led funding round Heidi
85 General Catalyst led growth investment Heidi
70 Heidi reached $50M ARR
55 Heidi launched Evidence
55 Heidi partnered with R1 RCM R1 RCM
55 Bret Engemann selected Heidi Heidi
50 Phoenix Court participated in funding Heidi
50 Point72 Asset Management participated in funding Heidi
50 Headline participated in funding Heidi
50 Beth Israel Lahey Health expanded deployment Heidi
45 Heidi shipped Remote
40 Heidi named Toronto headquarters Canada
35 Simon Kos joined Heidi Heidi
per
Heidi is the subject of the event, raising $340 million at a $900 million valuation to expand from AI clinical documentation into supervised agentic clinical workflows. The capital strengthens its balance sheet and global expansion capacity.
Importance 100.0 Sentiment 70.0
priv
Blackbird II ApS led Heidi's $100 million Series C and has backed the company since its pre-seed in 2021, reinforcing its position in Australian healthcare AI investing.
Importance 70.0 Sentiment 45.0
priv
General Catalyst's Customer Value Fund led the $240 million growth investment, gaining large-scale exposure to Heidi's expansion into agentic clinical workflows.
Importance 70.0 Sentiment 45.0
per
Co-founder and CEO Thomas Kelly is the public face of the raise, framing the round as the shift from documenting care to helping clinicians act on it under supervision.
Importance 60.0 Sentiment 40.0
priv
Phoenix Court participated as an existing investor in Heidi's Series C, maintaining its stake in the company.
Importance 40.0 Sentiment 35.0
priv
Point72 Asset Management participated as an existing investor in Heidi's Series C, maintaining its stake in the company.
Importance 40.0 Sentiment 35.0
priv
Headline participated as an existing investor in Heidi's Series C, with partner Taylor Brandt citing administrative burden and clinician burnout as drivers of the investment.
Importance 40.0 Sentiment 35.0
priv
Beth Israel Lahey Health expanded Heidi's AI scribe technology to all of its physicians, serving as a flagship US deployment validating Heidi's enterprise adoption.
Importance 30.0 Sentiment 20.0
per
Bret Engemann selected Heidi as sole supplier for Bret Engemann Midlands, described as the largest clinical AI procurement in NHS history, anchoring Heidi's UK presence.
Importance 30.0 Sentiment 20.0
per
Pranav Singhvi, co-founder and partner at General Catalyst's Customer Value Fund, led the $240 million growth investment and publicly endorsed Heidi's trust within complex health systems.
Importance 30.0 Sentiment 30.0
per
Michael, general partner at Blackbird II ApS, led the Series C and cited Heidi's proprietary models and clinical understanding as the basis for the investment.
Importance 30.0 Sentiment 30.0
cnt
The United States is a key expansion market for Heidi, with Beth Israel Lahey Health as a flagship deployment and Toronto named as the North American headquarters.
Importance 25.0 Sentiment 15.0
per
Waleed Mussa is a co-founder of Heidi, sharing in the company's growth and increased valuation.
Importance 25.0 Sentiment 30.0
per
Liu Yu is a co-founder of Heidi, sharing in the company's growth and increased valuation.
Importance 25.0 Sentiment 30.0
cnt
Australia is Heidi's home market and founding location, benefiting from the growth of a Melbourne-founded healthcare AI company attracting major global capital.
Importance 25.0 Sentiment 20.0
+ 10 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.